Background: There is a growing number of cohorts and registries collecting phenotypic and genotypic data from groups of multiple sclerosis patients. Improved awareness and better coordination of these efforts is needed. Objective: The purpose of this report is to provide a global landscape of the major longitudinal MS patient data collection efforts and share recommendations for increasing their impact. Methods: A workshop that included over 50 MS research and clinical experts from both academia and industry was convened to evaluate how current and future MS cohorts could be better used to provide answers to urgent questions about progressive MS.
Introduction
Although clinical trials are the gold standard for obtaining rigorous clinical data, their focus on individual agents and their relatively short duration limit their value for answering critical questions related to the evolution of multiple sclerosis (MS), particularly as it transitions into the progressive phase. For most individuals with MS, the progressive course can take more than 10 years to develop and then evolves over many decades, thus much longer follow-up is needed. Registries and cohorts that follow patients over a long time in a real-world environment have the potential to identify factors contributing to disability progression, individuals who are likely to benefit from early treatment, and the most effective treatment approach. Furthermore, if detailed physician-and patientreported data are accompanied by both magnetic resonance imaging (MRI) of the central nervous system (CNS) and biological samples, significant insight into the pathophysiology of progressive MS could be achieved, which would likely accelerate development of disease-modifying treatments.
Substantial investments are being made in a growing number of efforts collecting detailed phenotypic and genotypic data from groups of MS patients. Improved awareness of existing and planned cohorts and registries is needed to better coordinate these efforts and maximize the impact of the limited resources available to support them. Greater coordination will reduce duplication, enhance scientific credibility, and sharpen the focus on the most critical unanswered questions in MS. The purpose of this report is to provide a landscape of the current and planned longitudinal MS patient data collection efforts and propose recommendations for increasing their impact. Landscape MS cohort and registry studies have provided fundamental information about MS prevalence and incidence, rates of disability progression, and life expectancy. More contemporary studies of correlations between outcome and demographic/clinical data, 1 the presence or absence of associations between exposure and MS risk, 2-4 disease-modifying therapy use and disability progression, 5 and a proposed algorithm defining secondary progressive MS 6 have added to our understanding of the natural history of MS.
A growing number of data collection efforts are underway (Table 1) . These efforts differ in their genesis, recruitment criteria, types and frequencies of data collected (clinical, patient-reported outcomes, biospecimens, imaging), catchment area, and duration of follow-up, among others.
The Swedish MS Registry (EIMS) is an example of a clinical data set that has contributed to our understanding of the impact of disease-modifying therapy. The effort has enrolled approximately 80% of patients with MS in Sweden. Due to the use of a national personal ID in Sweden, data can be linked with other Swedish databases to investigate associations between MS and factors such as employment-related factors, co-morbidities, and other epidemiological factors. Similarly, the Danish Multiple Sclerosis Registry (DMSR) has enrolled nearly all patients with MS in Denmark and has advanced the understanding of MS epidemiology.
MSBase is a physician-driven observational registry that is based in Australia and has recruited more than 42,000 participants from 38 countries. Although this collection does not include biospecimens or imaging data, its large size and broad catchment area position it to address critical questions concerning the impact of disease-modifying treatment on the natural history of MS.
Other cohorts have been prospectively designed primarily for research purposes. 
Strengths and limitations of existing cohorts
Existing cohorts have amassed large collections of data, and several have also established accompanying biospecimen repositories. Several cohorts are working toward standardization of data and the methods for biospecimen, imaging, and data collection. 7 Others are working toward creating standardized imaging protocols. Some registries are able to link to other databases (i.e. payor databases), which should enhance their ability to advance knowledge of the natural history of MS and address critical questions related to response to therapy and disability progression.
Many (but not all) efforts have been designed without a specific hypothesis and participant selection criteria. This "convenience cohort" approach allows the flexibility to ask different questions, but is limited by the unknown generalizability of the observations and conclusions. In addition, harmonizing data from different cohorts is often difficult due to the use of different data elements as well as incompatible platforms and standards (often developed "in house"). Changes in technology can also make comparisons challenging. Many cohorts are not readily accessible to other qualified investigators. Inconsistencies can result from different and evolving criteria used for diagnosing and defining MS subtypes, time to an event such as progressive disease, follow-up times, terminology, data collection methods, and physician perceptions and opinions. Unlike clinical trials, randomization is not possible, which introduces a risk for biases and confounders that can make interpretation of the results challenging. Cohorts that rely on patient-reported outcomes may also contain recall and referral bias.
Recommendations
In February 2016, the US National Institute of Neurological Disorders and Stroke (NINDS) and the National Multiple Sclerosis Society convened a 
Recommendation 5: encourage technological innovation
Researchers should continue to utilize new technologies such as electronic health records and data collection methods. The utility of these approaches will be greatly enhanced by the creation of a minimum set of clinical and imaging standards to be used in all MS interactions. Likewise, investigators should incorporate guidelines for biospecimen collection, 7 and centralization of these repositories should be encouraged.
Recommendation 6: develop a universal informed consent process
Patient privacy and associated laws, including Health Insurance Portability and Accountability Act (HIPAA) in the United States, vary across countries, and consent forms should be developed to allow sharing of data with other countries. Restrictive consent forms can hamper research, but overly broad consent may make obtaining approval from local institutional review boards difficult.
Recommendation 7: provide sustainable funding
Cohorts are largely funded by grants with terms limited to 2-5 years. The most important unanswered questions in progressive MS will require following cohorts of patients for 10 years or longer, and thus, more sustained funding will be required. Better coordination and less duplication of data collection efforts should optimize the use of limited resources and allow for more sustained investments.
Conclusion
Despite significant investments in MS cohort studies, major gaps in our understanding of the natural history of MS progression remain. Better coordination, increased leveraging of evolving technology, a focus on the most important unanswered questions, improved access, and more sustained funding are key requirements for closing the gaps in our understanding of progressive MS. This knowledge will likely accelerate the development of effective therapies for progressive MS.
